Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Lengauer

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|June 16, 2005
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cellsKurtis E Bachman, Jason Sager, Ian Cheong, et al.
Molecular Cancer Therapeutics|May 20, 2016
Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective InhibitorHélène Bonnevaux, Olivier Lemaitre, Loic Vincent, et al.
Gastroenterology|June 10, 2006
Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic optionsEike Gallmeier, Eric S Calhoun, Carlo Rago, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
PRL-3 expression in metastatic cancersAlberto Bardelli, Saurabh Saha, Jason A Sager, et al.
Oncotarget|December 24, 2010
PI3Kα inhibitors that inhibit metastasisOleg Schmidt-Kittler, Jiuxiang Zhu, Jian Yang, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Single-vector inducible lentiviral RNAi system for oncology target validationDmitri Wiederschain, Susan Wee, Lin Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Crystal structure of human CDK4 in complex with a D-type cyclinPhilip J Day, Anne Cleasby, Ian J Tickle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal TumorsYemarshet K Gebreyohannes, Agnieszka Wozniak, Madalina-Elena Zhai, et al.
Cancer Research|June 10, 2010
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cellsZainab Jagani, Dmitri Wiederschain, Alice Loo, et al.
Nature Medicine|February 22, 2005
Contribution of bone marrow-derived endothelial cells to human tumor vasculatureBrock A Peters, Luis A Diaz, Kornelia Polyak, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|June 16, 2005
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cellsKurtis E Bachman, Jason Sager, Ian Cheong, et al.
Molecular Cancer Therapeutics|May 20, 2016
Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective InhibitorHélène Bonnevaux, Olivier Lemaitre, Loic Vincent, et al.
Gastroenterology|June 10, 2006
Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic optionsEike Gallmeier, Eric S Calhoun, Carlo Rago, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
PRL-3 expression in metastatic cancersAlberto Bardelli, Saurabh Saha, Jason A Sager, et al.
Oncotarget|December 24, 2010
PI3Kα inhibitors that inhibit metastasisOleg Schmidt-Kittler, Jiuxiang Zhu, Jian Yang, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Single-vector inducible lentiviral RNAi system for oncology target validationDmitri Wiederschain, Susan Wee, Lin Chen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Crystal structure of human CDK4 in complex with a D-type cyclinPhilip J Day, Anne Cleasby, Ian J Tickle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal TumorsYemarshet K Gebreyohannes, Agnieszka Wozniak, Madalina-Elena Zhai, et al.
Cancer Research|June 10, 2010
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cellsZainab Jagani, Dmitri Wiederschain, Alice Loo, et al.
Nature Medicine|February 22, 2005
Contribution of bone marrow-derived endothelial cells to human tumor vasculatureBrock A Peters, Luis A Diaz, Kornelia Polyak, et al.
Pageof 8